Prudhomme Thomas, Boissier Romain, Hevia Vital, Campi Riccardo, Pecoraro Alessio, Breda Alberto, Territo Angelo
Department of Urology, Rangueil University Hospital, Toulouse, France -
Department of Urology, La Conception University Hospital, Marseille, France.
Minerva Urol Nephrol. 2023 Feb;75(1):17-30. doi: 10.23736/S2724-6051.22.04972-2. Epub 2022 Sep 12.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common causes of a need of renal replacement therapy. The need (elective vs. systematic) and timing of native kidney nephrectomy (before, after or during kidney transplantation) is a matter of debate and alternatives to surgery, mainly transcatheter arterial embolization have been explored. We performed a systematic review to report all available evidence on postintervention outcomes of native nephrectomy and arterial embolization in ADPKD patients.
A search on Medline, Embase, and Cochrane databases was performed to identify all studies reporting outcomes of native nephrectomy or arterial embolization in APKDs.
Concerning native nephrectomy, a total of 3626 patients in 37 studies were included with 735, 210 and 2681 patients who underwent native nephrectomy respectively before, after or during kidney transplantation. Major complications were 12.2% in unilateral nephrectomy before transplantation, 25.0% in bilateral nephrectomy before transplantation, 17.7% in unilateral nephrectomy during transplantation, 20.8% in bilateral nephrectomy during transplantation and 23.8% in unilateral and bilateral nephrectomy after transplantation. A total of 230 patients in 7 series of arterial embolization were included. All arterial embolization were performed before transplantation. Mean volume reduction ranged from 36.3% at 3 months to 49% at 6 months. The major postintervention complication rate was 1%.
Unilateral native nephrectomy before kidney transplantation was associated with the lowest major postoperative complication rate and appears to be the preferred strategy. Arterial embolization reduces kidney volume by 49% at 6 months. Arterial embolization could be considered when the reduction in size of the native kidney is not urgent.
常染色体显性遗传性多囊肾病(ADPKD)是需要进行肾脏替代治疗的最常见病因之一。自体肾切除术的必要性(选择性与系统性)及时机(在肾移植前、后或期间)存在争议,并且人们已经探索了手术替代方案,主要是经导管动脉栓塞术。我们进行了一项系统评价,以报告关于ADPKD患者自体肾切除术和动脉栓塞术后干预结果的所有现有证据。
对Medline、Embase和Cochrane数据库进行检索,以识别所有报告APKD患者自体肾切除术或动脉栓塞术结果的研究。
关于自体肾切除术,37项研究共纳入3626例患者,其中分别有735例、210例和2681例患者在肾移植前、后或期间接受了自体肾切除术。主要并发症在移植前单侧肾切除术中为12.2%,移植前双侧肾切除术中为25.0%,移植期间单侧肾切除术中为17.7%,移植期间双侧肾切除术中为20.8%,移植后单侧和双侧肾切除术中为23.8%。7项动脉栓塞术系列研究共纳入230例患者。所有动脉栓塞术均在移植前进行。平均体积缩小率在3个月时为36.3%,6个月时为49%。干预后主要并发症发生率为1%。
肾移植前单侧自体肾切除术的术后主要并发症发生率最低,似乎是首选策略。动脉栓塞术在6个月时可使肾脏体积缩小49%。当自体肾体积缩小不紧急时,可考虑动脉栓塞术。